CME Information

Activity Title: Reversing DOACs: Providing Answers on Why, When, and How?

Topic: Anticoagulants

Accreditation Type: AMA PRA Category 1 Credit(s)™; 1 ABIM MOC knowledge point

Release Date: July 20, 2021

Expiration Date: October 19, 2021

Estimated Time to Complete Activity: 60 minutes

EDUCATIONAL ACTIVITY LEARNING OBJECTIVES
Upon completing this activity, learners will be able to:

• Discuss with clinical colleagues the appropriate use of specific DOAC reversal agents
• Explain efficacy and safety of the pharmacotherapeutic options for DOAC reversal
• Advise on appropriate institutional approaches to DOAC reversal agents

FACULTY
Deborah Siegal, MD, MSc, FRCPC (Co-Chair)
Associate Professor, Department of Medicine
University of Ottawa
Associate Scientist, Clinical Epidemiology Program
Ottawa Hospital Research Institute
Ottawa, Ontario

Geoff Barnes, MD, MSc (Co-Chair)
Assistant Professor of Internal Medicine
Vascular and Cardiovascular Medicine
Director, Vascular Medicine Fellowship
Frankel Cardiovascular Center
University of Michigan
Ann Arbor, Michigan

F. A. (Erik) Klok, MD, PhD
Clinical Staff Member, Thrombosis and Hemostasis
Department of Medicine
Leiden University Medical Center
Leiden, the Netherlands

Allison E. Burnett, PharmD, PhC, CACP
Antithrombosis Stewardship Pharmacist
University of New Mexico Hospital
Adjunct Associate Clinical Professor
University of New Mexico College of Pharmacy
President-Anticoagulation Forum
Albuquerque, New Mexico

METHOD OF PARTICIPATION/HOW TO RECEIVE CREDIT

1. There are no fees for participating in and receiving credit for this activity
2. Review the activity objectives and CME/CE information
3. Complete the CME/CE activity
4. Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
5. Complete the CME/CE evaluation form. This form provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
6. Credit documentation/reporting:
   • If you are requesting AMA PRA Category 1 Credit(s)™ or a certificate of participation—your CME/CE certificate will be available for download
   • If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards

PROVIDER
This activity is jointly provided by The France Foundation and ISTH.

TARGET AUDIENCE
This activity is intended for members of the hematology team, including hematologists, nurse practitioners, and PAs specializing in hematology.

STATEMENT OF NEED
This program is designed to provide education for the hematology team to prepare them to provide clinical and institutional consultations on the pharmacologic options to manage DOAC-related bleeding, their specific indications, and safety and efficacy considerations.

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and International Society on Thrombosis and Haemostasis. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION
Physicians: The France Foundation designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

DISCLOSURE POLICY
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and International Society on Thrombosis and Haemostasis (ISTH) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ISTH resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and ISTH seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ISTH are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, and other members at The France Foundation who control content have no relevant financial relationships to disclose.

The planners, reviewers, editors, staff, CME committee, and other members at ISTH who control content have no relevant financial relationships to disclose.

Faculty Disclosures
The faculty listed below report that they have no relevant financial relationships to disclose:

• Allison E. Burnett, PharmD, PhC, CACP

The faculty listed below report that they have relevant financial relationships to disclose:

• Deborah Siegal, MD, MSc, FRCPC, has received speaker fees from Aspen Pharma, BMS‐Pfizer, Leo Pharma, Novartis, Portola, and Servier
• Geoff Barnes, MD, MSc, is a consultant for Pfizer/Bristol Myers Squibb, Janssen, and AMAG Pharmaceuticals
• F. A. (Erik) Klok, MD, PhD, has received research support by LUMC from Bayer, Actelion, The Netherlands Organization for Health Research and Development, the Dutch Thrombosis Association, and the Dutch Heart Foundation

DISCLOSURE OF UNLABELED USE
TFF and ISTH require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ISTH do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

COMMERCIAL SUPPORT ACKNOWLEDGEMENT
This activity is supported by an educational grant from Alexion Pharmaceuticals, Inc.

DISCLAIMER
The France Foundation and International Society on Thrombosis and Haemostasis present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, International Society on Thrombosis and Haemostasis, and the commercial supporter assume no liability for the information herein.

COPYRIGHT INFORMATION
Copyright © 2021 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

• The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
• Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.

PRIVACY POLICY
The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except when such information is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.

Additional information regarding The France Foundation's Privacy Policy can be viewed at www.francefoundation.com/privacy-policy.

CONTACT INFORMATION
If you have questions about this activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.